Thursday, November 6, 2025 at 12-1pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Biliary tract cancer (BTC) is a rare and aggressive malignancy with limited treatment options, particularly in the advanced setting. This webinar will explore the role of HER2 as an actionable biomarker in BTC, and highlight recent clinical data supporting HER2-targeted therapies. Managed care professionals will gain insights into the evolving treatment landscape, the importance of timely access to molecular testing and therapy, and strategies to optimize coverage decisions. Join us for a timely discussion on how managed care professionals can support improved outcomes for patients with HER2-positive BTC.

Learning Objectives

By the end of this webinar, participants will be able to:

• Evaluate the evolving treatment landscape for HER2-positive biliary tract cancer (BTC) and its implications for managed care decision making.
• Interpret the role of actionable biomarkers, including HER2, in BTC and understand how molecular profiling can guide targeted therapy selection.
• Assess the clinical and economic impact of timely access to HER2-targeted therapies in the second-line setting for advanced BTC.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.